MA49425A - Compositions comprenant des souches bactériennes - Google Patents

Compositions comprenant des souches bactériennes

Info

Publication number
MA49425A
MA49425A MA049425A MA49425A MA49425A MA 49425 A MA49425 A MA 49425A MA 049425 A MA049425 A MA 049425A MA 49425 A MA49425 A MA 49425A MA 49425 A MA49425 A MA 49425A
Authority
MA
Morocco
Prior art keywords
compositions containing
bacterial strains
containing bacterial
strains
compositions
Prior art date
Application number
MA049425A
Other languages
English (en)
Inventor
Suaad Ahmed
Anna Ettorre
Parthena Fotiadou
Imke Elisabeth MULDER
Helene Savignac
Joseph Roby Iringan Urcia
Samantha Yuille
Original Assignee
4D Pharma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1709468.1A external-priority patent/GB201709468D0/en
Priority claimed from GBGB1709534.0A external-priority patent/GB201709534D0/en
Priority claimed from GBGB1712851.3A external-priority patent/GB201712851D0/en
Priority claimed from GBGB1803826.5A external-priority patent/GB201803826D0/en
Priority claimed from GBGB1805991.5A external-priority patent/GB201805991D0/en
Priority claimed from GBGB1805990.7A external-priority patent/GB201805990D0/en
Priority claimed from GBGB1805989.9A external-priority patent/GB201805989D0/en
Priority claimed from GBGB1806779.3A external-priority patent/GB201806779D0/en
Priority claimed from GBGB1806780.1A external-priority patent/GB201806780D0/en
Application filed by 4D Pharma Res Ltd filed Critical 4D Pharma Res Ltd
Publication of MA49425A publication Critical patent/MA49425A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA049425A 2017-06-14 2018-06-14 Compositions comprenant des souches bactériennes MA49425A (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB1709468.1A GB201709468D0 (en) 2017-06-14 2017-06-14 Compositions comprising bacterial strains
GBGB1709534.0A GB201709534D0 (en) 2017-06-15 2017-06-15 Compositions comprising bacterial strains
GBGB1712851.3A GB201712851D0 (en) 2017-08-10 2017-08-10 Compositions comprising bacterial strains
GBGB1803826.5A GB201803826D0 (en) 2018-03-09 2018-03-09 Compositions comprising bacterial strains
GBGB1805991.5A GB201805991D0 (en) 2018-04-11 2018-04-11 Compositions comprising bacterial strains
GBGB1805990.7A GB201805990D0 (en) 2018-04-11 2018-04-11 Compostions comprising bacterial strains
GBGB1805989.9A GB201805989D0 (en) 2018-04-11 2018-04-11 Compositions comprising bacterial strains
GBGB1806779.3A GB201806779D0 (en) 2018-04-25 2018-04-25 Compositions comprising bacterial strains
GBGB1806780.1A GB201806780D0 (en) 2018-04-25 2018-04-25 Compositions comprising bacterial strains

Publications (1)

Publication Number Publication Date
MA49425A true MA49425A (fr) 2020-04-22

Family

ID=62784100

Family Applications (3)

Application Number Title Priority Date Filing Date
MA53937A MA53937B1 (fr) 2017-06-14 2018-06-14 Compositions comprenant des souches bactériennes
MA049425A MA49425A (fr) 2017-06-14 2018-06-14 Compositions comprenant des souches bactériennes
MA49010A MA49010B1 (fr) 2017-06-14 2018-06-14 Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA53937A MA53937B1 (fr) 2017-06-14 2018-06-14 Compositions comprenant des souches bactériennes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA49010A MA49010B1 (fr) 2017-06-14 2018-06-14 Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations

Country Status (25)

Country Link
US (3) US11660319B2 (fr)
EP (4) EP3804737B1 (fr)
JP (4) JP6837581B2 (fr)
KR (2) KR102519483B1 (fr)
CN (2) CN111032061A (fr)
AU (4) AU2018285453B2 (fr)
BR (2) BR112019026667A2 (fr)
CA (3) CA3066561C (fr)
CY (2) CY1123565T1 (fr)
DK (2) DK3804737T3 (fr)
ES (2) ES2917415T3 (fr)
HR (2) HRP20220747T1 (fr)
HU (2) HUE052258T2 (fr)
IL (3) IL292373A (fr)
LT (2) LT3804737T (fr)
MA (3) MA53937B1 (fr)
MD (2) MD3600364T2 (fr)
MX (1) MX2021006456A (fr)
PL (2) PL3600364T3 (fr)
PT (2) PT3804737T (fr)
RS (2) RS63393B1 (fr)
SG (2) SG11201912156QA (fr)
SI (2) SI3600364T1 (fr)
TW (2) TW201919668A (fr)
WO (2) WO2018229236A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052258T2 (hu) * 2017-06-14 2021-04-28 4D Pharma Res Ltd Megasphaera nemzetségbe tartozó baktériumtörzset tartalmazó készítmény, és alkalmazása
CN112601534A (zh) * 2018-05-11 2021-04-02 4D制药研究有限公司 包含细菌菌株的组合物
EP3893905A1 (fr) * 2018-12-12 2021-10-20 4D Pharma Research Limited Compositions comprenant des souches bactériennes
JP2022535761A (ja) * 2019-06-03 2022-08-10 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 敗血症および壊死性腸炎誘発神経発達不全の予防のためのプレバイオティクス製剤
JP2022540576A (ja) 2019-07-05 2022-09-16 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
CN110420228A (zh) * 2019-09-16 2019-11-08 山东大学齐鲁医院 脆弱拟杆菌ych46在制备治疗或辅助治疗高血压的药物中的应用
US20220364056A1 (en) * 2019-09-25 2022-11-17 Philipps-Universität Marburg Short-chain fatty acid pentanoate as enhancer for cellular therapy and anti-tumor therapy
MX2023003089A (es) 2020-09-18 2023-05-09 Evelo Biosciences Inc Formas farmaceuticas solidas de bacterias.
CN112239741B (zh) * 2020-12-10 2022-05-27 慕恩（广州）生物科技有限公司 一种Megasphaera属的细菌MNC-992及其培养方法和应用
JP2024501481A (ja) 2020-12-14 2024-01-12 エヴェロ バイオサイエンシズ，インコーポレーテッド 細胞外小胞調製物
WO2022187578A1 (fr) 2021-03-05 2022-09-09 Evelo Biosciences, Inc. Formes posologiques solides
KR20240006543A (ko) 2021-04-08 2024-01-15 에벨로 바이오사이언시즈, 인크. 박테리아를 함유하는 약학적 조성물
WO2022239013A1 (fr) * 2021-05-12 2022-11-17 Biomica Ltd. Microorganisme du microbiome et ses utilisations
EP4404921A1 (fr) 2021-09-24 2024-07-31 Evelo Biosciences, Inc. Formes pharmaceutiques solides contenant des bactéries et des vésicules extracellulaires microbiennes
CN114276948B (zh) * 2021-11-08 2023-06-20 泸州老窖股份有限公司 产己酸的赖氨酸芽孢杆菌及其用途
WO2023107537A1 (fr) 2021-12-07 2023-06-15 Evelo Biosciences, Inc. Compositions d'anticorps et procédés d'utilisation avec des vésicules extracellulaires et microbes
WO2023114293A1 (fr) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Dosages de vésicules extracellulaires
WO2024015522A1 (fr) 2022-07-13 2024-01-18 Evelo Biosciences, Inc. Procédés d'analyse de vésicules extracellulaires et de microbes
WO2024076723A1 (fr) 2022-10-07 2024-04-11 Evelo Biosciences, Inc. Traitement de vésicules extracellulaires
WO2024102226A1 (fr) 2022-10-14 2024-05-16 Evelo Biosciences, Inc. Procédés de dosage de substances médicamenteuses et de produits médicamenteux à l'aide de lignées cellulaires comportant des gènes rapporteurs inductibles par nf-kb
CN117821621B (zh) * 2023-12-15 2024-08-13 深圳未知君生物科技有限公司 一种马氏巨球菌的分子标记及其应用

Family Cites Families (405)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
JPS5031249B1 (fr) 1970-12-17 1975-10-08
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
JPS5710876B2 (fr) 1974-04-08 1982-03-01
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4138498A (en) * 1976-12-07 1979-02-06 W. R. Grace & Co. Ruminant feed additive
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
JPS5557520A (en) 1978-10-26 1980-04-28 Nisshin Flour Milling Co Ltd Preparation of carcinostatic substance
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
EP0433299B1 (fr) 1988-08-02 1998-05-06 Gastro Services Pty. Limited (ACN 002 994 890) Traitement de troubles gastro-intestinaux
KR100225087B1 (ko) 1990-03-23 1999-10-15 한스 발터라벤 피타아제의 식물내 발현
AU639570B2 (en) 1990-05-09 1993-07-29 Novozymes A/S A cellulase preparation comprising an endoglucanase enzyme
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5443951A (en) 1992-07-20 1995-08-22 Kabushiki Kaisha Yakult Honsha Species-specific oligonucleotides for bifidobacteria and a method of detection using the same
JPH08504327A (ja) 1992-12-10 1996-05-14 ギスト ブロカデス ナムローゼ フェンノートシャップ 糸状菌における異種タンパクの生産
US5741665A (en) 1994-05-10 1998-04-21 University Of Hawaii Light-regulated promoters for production of heterologous proteins in filamentous fungi
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM823094A0 (en) 1994-09-16 1994-10-13 Goodman Fielder Limited Probiotic compositions
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
RU2078815C1 (ru) 1995-01-17 1997-05-10 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Штамм бактерий bifidobacterium breve, используемый для получения бактерийных лечебно-профилактических бифидосодержащих препаратов
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk インターフェロン産生増強剤
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
CA2232001C (fr) * 1995-09-15 2002-12-10 Dale N. Gerding Procedes et compositions pour prevenir et traiter les maladies associees a clostridium difficile
AUPN698495A0 (en) 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
SE508045C2 (sv) 1996-02-26 1998-08-17 Arla Ekonomisk Foerening Adhesionsinhibitorer, preparat innehållande desamma och förfarande för framställning därav
AUPN881396A0 (en) 1996-03-20 1996-04-18 Arnott's Biscuits Limited Enhancement of microbial colonization of the gastrointestinal tract
JP4282763B2 (ja) 1996-03-20 2009-06-24 ザ、ユニバーシティ、オブ、ニュー、サウス、ウェイルズ 消化管内の微生物個体数の変更
WO1997035956A1 (fr) 1996-03-27 1997-10-02 Novo Nordisk A/S Champignons filamenteux carences en proteases alcalines
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
WO1998043081A1 (fr) 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Traitement de troubles gastro-intestinaux au moyen de modulateurs du recepteur active de la proliferation des peroxysomes (ppar)
SE511524C2 (sv) 1997-06-02 1999-10-11 Essum Ab Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6652866B1 (en) 1997-10-14 2003-11-25 David W. Hertha Method for treating diseases of fungal, yeast, and prion protein etiology
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
DE19826928A1 (de) 1998-06-17 1999-12-23 Novartis Consumer Health Gmbh Arzneimittel, lebensfähige anaerobe Bakterien enthaltend, die die Sulfatreduktion sulfatreduzierender Bakterien hemmen
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7090973B1 (en) 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
AUPQ137699A0 (en) * 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
JP2003508389A (ja) 1999-08-27 2003-03-04 エリ リリー アンド カンパニー ビアリール−オキサ（チア）ゾール誘導体およびそのｐｐａｒモジュレーターとしての使用
BR0108164B1 (pt) 2000-02-08 2014-06-17 Dsm Ip Assets Bv Uso de pelo menos uma protease estável em ácido, processo para melhorar o valor nutritivo de um alimento para animal, aditivo de alimento para animal, composição de alimento para animal, e, processo para tratar proteínas vegetais para uso em alimento para animal.
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2002042328A2 (fr) 2000-11-27 2002-05-30 Washington University Methode pour etudier l'effet d'une flore microbienne commensale sur l'intestin d'un mammifere, et traitement d'une maladie gastro-intestinale fonde sur cette methode
BR0116788A (pt) * 2000-12-21 2004-02-03 Nestle Sa Cepa de lactobacillus que produz levano e seu uso em produtos alimentìcios para seres humanos ou para animais de estimação
DE10101793A1 (de) 2001-01-17 2002-08-01 Manfred Nilius Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
EP1227152A1 (fr) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Souche bactérienne et genome de bifidobacterium
KR100437497B1 (ko) 2001-03-07 2004-06-25 주식회사 프로바이오닉 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제
EP1243273A1 (fr) 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition contenant un agent prebiotique pour le traitement d'inflammation et d'activation anormal des agents immunitaires non-spécifiques
EP1389464A4 (fr) 2001-04-06 2005-06-22 Combi Co Compositions contenant une bacterie pouvant convertir de l'acide lactique en acide butyrique, et methode utilisant ces compositions pour prevenir ou traiter l'hyperlactacidemie dans le systeme digestif ou le cancer du colon
EP1379552B2 (fr) 2001-04-20 2014-11-19 The Institute for Systems Biology Ligands de recepteur de type 5 et procedes d'utilisation
EP1260227A1 (fr) 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. L'acide lipoteichoique des bacteries lactiques et son utilisation pour moduler des responses immunitaites induites par des bacteries a gram negatif, gram positif
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
MXPA04001999A (es) 2001-09-05 2004-07-16 Vsl Pharmaceuticals Inc Bacterias de acido lactico que comprende dinucleotidos de citosina-guanina no metilados para usarse en terapia.
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
AU2002346504A1 (en) 2001-11-27 2003-06-10 Astrazeneca Ab Therapeutic protein and treatments
CA2476755C (fr) 2001-12-17 2014-08-26 Corixa Corporation Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
DE10206995B4 (de) 2002-02-19 2014-01-02 Orthomol Pharmazeutische Vertriebs Gmbh Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
JP2003261453A (ja) 2002-03-11 2003-09-16 Nippon Berumu Kk Ｅ．フェカリスからなる抗腫瘍剤及び放射線防護剤
WO2004003235A2 (fr) 2002-06-28 2004-01-08 Puleva Biotech, S.A. Souches probiotiques, leur procede de selection, compositions associees et leur utilisation
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
US20040230963A1 (en) * 2003-05-12 2004-11-18 Rothman Michael A. Method for updating firmware in an operating system agnostic manner
EP1481681A1 (fr) 2003-05-30 2004-12-01 Claudio De Simone Combinaisons de bactéries lactiques et leur compositions
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
AU2003247193A1 (en) 2003-07-23 2005-02-04 M.D.Lab Corp. Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus
US7485325B2 (en) 2003-08-06 2009-02-03 Gayle Dorothy Swain Animal food supplement compositions and methods of use
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
EP1667680A4 (fr) 2003-08-29 2008-10-08 Aton Pharma Inc Methodes combinees de traitement du cancer
US20050163764A1 (en) 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
GB0323039D0 (en) 2003-10-01 2003-11-05 Danisco Method
ES2314461T3 (es) 2003-10-24 2009-03-16 N.V. Nutricia Composicion simbiotica para bebes.
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
CA2550106A1 (fr) 2003-12-17 2005-06-30 N.V. Nutricia Bacteries de production d'acide lactique et fonction pulmonaire
ES2235642B2 (es) 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
WO2005093049A1 (fr) 2004-03-22 2005-10-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Inactivation cellulaire et virale
JP2007535924A (ja) 2004-05-07 2007-12-13 − グスタフ ユングレン、ハンス ワクチン用アジュバントとしてのフラジェリンの使用
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
NZ586338A (en) 2004-06-07 2012-02-24 Qu Biolog Inc Bacterial compositions for the treatment of cancer
US8962683B2 (en) 2004-06-30 2015-02-24 Nutrition Sciences Nv Medium chain fatty acids applicable as anti-microbial agents
ES2286558T5 (es) 2004-08-24 2013-10-15 N.V. Nutricia Composición nutritiva que comprende transgalactooligosacáridos indigeribles y sacáridos de galactosa digeribles
US20060062742A1 (en) 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for reduction of human malodor
JP5371169B2 (ja) 2004-09-24 2013-12-18 コンビ株式会社 薬剤耐性菌感染防除剤
KR100468522B1 (ko) 2004-10-12 2005-01-31 주식회사 프로바이오닉 코로나바이러스와 돼지 써코바이러스 2형의 생육을 억제하는 신규한 내산성 프로바이오틱 엔테로코커스훼시움 프로바이오-63
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
ITMI20042189A1 (it) 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
ES2524344T3 (es) 2005-02-28 2014-12-05 N.V. Nutricia Composición nutritiva con probióticos
WO2006102350A1 (fr) 2005-03-23 2006-09-28 Washington University In St. Louis Utilisation d'archees pour moduler les fonctions de capture des nutriments par la microbiote gastro-intestinale
WO2006102536A2 (fr) 2005-03-23 2006-09-28 University Of Southern California Traitement d'etats pathologiques par modulation du sulfure d'hydrogene produit par la proliferation bacterienne de l'intestin grele
JP2006265212A (ja) 2005-03-25 2006-10-05 Institute Of Physical & Chemical Research Ｉｌ−２１産生誘導剤
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
EP1714660A1 (fr) 2005-04-21 2006-10-25 N.V. Nutricia D'acide uronique et des probiotiques
US8603461B2 (en) 2005-04-26 2013-12-10 TEAGASC—The Agriculture and Food Development Authority Probiotic composition suitable for animals
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en) 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
JP2007084533A (ja) 2005-08-24 2007-04-05 Prima Meat Packers Ltd 免疫応答調節組成物及び該組成物を有効成分とする食品
US7625704B2 (en) 2005-08-31 2009-12-01 Fred Hutchinson Cancer Research Center Methods and compositions for identifying bacteria associated with bacteria vaginosis
CN101296706B (zh) 2005-09-01 2011-11-30 先灵公司 Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
US20090028840A1 (en) 2005-09-23 2009-01-29 Gwangju Institute Of Sciecne And Technology Compositions For Preventing Or Treating Arthritis Comprising Lactic Acid Bacteria and Collangen As Active Ingredients
EP1776877A1 (fr) 2005-10-21 2007-04-25 N.V. Nutricia Méthode de stimulation de la flore intestinale
MY144556A (en) 2005-10-24 2011-09-30 Nestec Sa Dietary fiber formulation and method of administration
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc 機能性食品
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
AU2006320604A1 (en) 2005-12-01 2007-06-07 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
US8889149B2 (en) 2006-02-16 2014-11-18 Wayne State University Use of flagellin to prevent and treat gram negative bacterial infection
US20080260906A1 (en) 2006-03-17 2008-10-23 Marko Stojanovic Compositions comprising probiotic and sweetener components
JP5031249B2 (ja) 2006-03-22 2012-09-19 学校法人北里研究所 炎症抑制作用のある菌体含有組成物
CA2652559A1 (fr) 2006-05-18 2007-11-29 Biobalance Llc Compositions biotherapeutiques et utilisations connexes
CA2655665A1 (fr) 2006-05-26 2007-12-06 Nestec S.A. Procedes d'utilisation d'extrait de touchi et compositions nutritionnelles d'extrait de touchi associees
WO2007140613A1 (fr) 2006-06-06 2007-12-13 Mcgill University Produit de lait fermenté et son utilisation
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US8691213B2 (en) 2006-08-04 2014-04-08 SHS International Protein free formula
WO2008031438A2 (fr) 2006-09-13 2008-03-20 Region Hovedstaden V/Gentofte Hospital Traitement de l'asthme, de l'eczéma et / ou d'allergies à l'aide d'organismes non pathogènes
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
KR20120038021A (ko) 2006-10-27 2012-04-20 화이자 프로덕츠 인코포레이티드 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법
WO2008053444A2 (fr) 2006-11-01 2008-05-08 The Procter & Gamble Company Méthodes visant à traiter un trouble respiratoire au moyen d'un traitement probiotique
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008064489A1 (fr) 2006-12-01 2008-06-05 Mcmaster University Probiotiques destinés à inhiber les inflammations
EP2102350A4 (fr) 2006-12-18 2012-08-08 Univ St Louis Microbiome intestinal en tant que biomarqueur et cible thérapeutique pour traiter l'obésité ou un trouble lié à l'obésité
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008083157A2 (fr) 2006-12-29 2008-07-10 Washington University In St. Louis Altération du pgc-1alpha, de l'ampk, du fiaf, ou du microbiote gastro-intestinal comme moyen pour moduler les réserves lipidiques de l'organisme et/ou la perte de poids chez un sujet
JP2008195635A (ja) 2007-02-09 2008-08-28 Crossfield Bio Inc 馬用乳酸菌製剤
MX2009008875A (es) 2007-02-28 2009-08-28 Mead Johnson Nutrition Co Producto que contiene probiotico inactivado para niños o infantes.
JP5538209B2 (ja) 2007-03-28 2014-07-02 アリメンタリー・ヘルス・リミテッド プロバイオティック性のビフィドバクテリウム菌株
AU2008231467A1 (en) 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic Bifidobacterium strains
AU2008245685B2 (en) 2007-04-24 2013-06-27 Kemin Industries, Inc. Broad-spectrum antibacterial and antifungal activity of Lactobacillus johnsonii D115
EP1997499A1 (fr) 2007-05-31 2008-12-03 Puleva Biotech, S.A. Microorganismes de lait maternel, compositions les contenant et leur utilisation pour le traitement de métastase
EP1997907A1 (fr) 2007-06-01 2008-12-03 Friesland Brands B.V. Bifidobactéries
EP1997905A1 (fr) 2007-06-01 2008-12-03 Friesland Brands B.V. Amplification d'acide nucléique
EP1997906A1 (fr) 2007-06-01 2008-12-03 Friesland Brands B.V. Lactobacillus
WO2008153377A1 (fr) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition avec une bifidobactérie non viable et un oligosaccharide non digestible
WO2009002145A1 (fr) 2007-06-26 2008-12-31 N.V. Nutricia Composition lipidique destinée à améliorer l'activité cérébrale
EP2179028B1 (fr) 2007-06-27 2014-08-13 Laboratorios Ordesa, S.l. Nouvelle souche de bifidobactérie et peptides actifs contre des infections par un rotavirus
HUP0700552A2 (en) 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
WO2009030254A1 (fr) 2007-09-04 2009-03-12 Curevac Gmbh Complexes d'arn et de peptides cationiques pour transfection et immunostimulation
US20100284979A1 (en) 2007-10-01 2010-11-11 University College Cork, National University Of Ireland, Cork Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria
DK2203551T3 (da) 2007-10-20 2013-10-28 Univ Liege Bifidobakterieart
ES2473625T3 (es) 2007-10-26 2014-07-07 Brenda E. Moore Composición probi�tica y métodos para inducir y mantener la pérdida de peso
EP2205642B1 (fr) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Compositions de polysaccharides non anticoagulants
EP2065048A1 (fr) 2007-11-30 2009-06-03 Institut Pasteur Utilisation d'une souche de L. casei pour la préparation d'une composition pour l'inhibition de l'activation de mastocytes
US9119414B2 (en) 2007-12-07 2015-09-01 N.V. Nutricia Bifidobacterium for dust mite allergy
WO2009079564A2 (fr) 2007-12-17 2009-06-25 Emory University Compositions immunogènes et leurs procédés d'utilisation
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
JP2011510684A (ja) 2008-02-06 2011-04-07 ザ プロクター アンド ギャンブル カンパニー 呼吸器状態に対する免疫反応を強化するための組成物、方法、及びキット
EP2103226A1 (fr) 2008-03-18 2009-09-23 Friesland Brands B.V. Produit alimentaire probiotique de longue durée
WO2009128950A2 (fr) 2008-04-18 2009-10-22 Vaxinnate Corporation Mutants par délétion de la flagelline et procédés d’utilisation
CA2722738C (fr) 2008-05-13 2017-04-25 Glycotope Gmbh Procede de fermentation
MX2008006546A (es) 2008-05-21 2009-11-23 Sigma Alimentos Sa De Cv Bifidobacteria productora de ácido fólico, composición alimenticia y uso de la bifidobacteria.
CN102940652B (zh) 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
CN101590081A (zh) 2008-05-28 2009-12-02 青岛东海药业有限公司 凸腹真杆菌和两形真杆菌制剂及其应用
WO2009149149A1 (fr) 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prévention ou traitement d'une maladie immunitaire par modification de populations microflorales
CN101596216A (zh) * 2008-06-06 2009-12-09 萧湘 预防或治疗糖尿病和相关病症的微生物制剂
EP2133088A3 (fr) 2008-06-09 2010-01-27 Nestec S.A. Rooibos et inflammation
WO2009151315A1 (fr) 2008-06-13 2009-12-17 N.V. Nutricia Composition nutritionnelle pour nourrissons nés par césarienne
WO2009154463A2 (fr) 2008-06-20 2009-12-23 Stichting Top Institute Food And Nutrition Le butyrate comme médicament permettant d'améliorer la perception viscérale chez l'homme
EP2138186A1 (fr) 2008-06-24 2009-12-30 Nestec S.A. Probiotiques, IgA de sécrétion et inflammation
WO2010002241A1 (fr) 2008-06-30 2010-01-07 N.V. Nutricia Composition nutritive pour bébés nés par césarienne
KR101017448B1 (ko) 2008-09-18 2011-02-23 주식회사한국야쿠르트 대장의 건강 증진 효능을 갖는 비피도박테리움 롱검 에이취와이8004 및 이를 유효성분으로 함유하는 제품
US20100074870A1 (en) 2008-09-19 2010-03-25 Bristol-Myers Squibb Company Probiotic infant products
US8137718B2 (en) 2008-09-19 2012-03-20 Mead Johnson Nutrition Company Probiotic infant products
KR101057357B1 (ko) 2008-09-22 2011-08-17 광주과학기술원 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
WO2010037408A1 (fr) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
US20110223137A1 (en) 2008-12-05 2011-09-15 Nestec S.A. Compositions for use in low-birth weight infants
CA2746805A1 (fr) 2008-12-19 2010-06-24 Nestec S.A. Prevention et traitement de la diarrhee a rotavirus
IT1392672B1 (it) 2009-01-12 2012-03-16 Wyeth Consumer Healthcare S P A Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina
BRPI1013688A8 (pt) 2009-03-05 2017-02-14 Abbott Lab Proteínas de ligação de il-17.
JP5710876B2 (ja) 2009-03-26 2015-04-30 クロスフィールドバイオ株式会社 新規ビフィドバクテリウム属微生物およびその利用
US8816067B2 (en) 2009-05-07 2014-08-26 Tate & Lyle Ingredients France SAS Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
CA2761444C (fr) 2009-05-11 2018-04-24 Nestec S.A. Lactobacillus johnsonii la1 ncc533 (cncm i-1225) et troubles immunitaires
EP2251022A1 (fr) 2009-05-11 2010-11-17 Nestec S.A. Micro-organismes sans réplication, et leur effet d'augmentation immunitaire
EP2251020A1 (fr) 2009-05-11 2010-11-17 Nestec S.A. Traitement haute température de courte durée qui génère des préparations microbiennes avec des profils anti-inflammatoires
KR20100128168A (ko) 2009-05-27 2010-12-07 중앙대학교 산학협력단 공액 리놀레산 생산능이 우수한 신규한 균주
US20100311686A1 (en) 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2010143940A1 (fr) 2009-06-12 2010-12-16 N.V. Nutricia Mélange synergique de bêta-galacto-oligosaccharides avec des liaisons bêta-1,3 et bêta-1,4/1,6
EP2443259A4 (fr) 2009-06-16 2012-10-10 Univ Columbia Biomarqueurs associés à l'autisme et utilisations de ces derniers
US9050276B2 (en) * 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2011005756A1 (fr) 2009-07-06 2011-01-13 Puretech Ventures, Llc Administration d'agents ciblés contre des niches de microbiote
WO2011011094A1 (fr) 2009-07-24 2011-01-27 Dowd Scot E Diagnostic, détection, quantification microbiens universels, et thérapie ciblée sur un échantillon
CA2770062A1 (fr) 2009-08-18 2011-02-24 Nestec S.A. Composition nutritionnelle comprenant des souches de bifidobacterium longum et reduisant des symptomes d'allergie alimentaire, en particulier chez des bebes et chez des enfants
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
GB2473294B (en) 2009-09-08 2014-07-09 Mclaren Automotive Ltd Dynamics control
CA2775050C (fr) 2009-09-23 2020-07-14 Thomas Julius Borody Therapie pour infections enteriques
EP2308498A1 (fr) 2009-09-30 2011-04-13 Nestec S.A. Administration de bifidobacterium rapide au cours de l'enfance pour empêcher une inflammation postérieure au cours de la vie
EP2486143A1 (fr) 2009-10-05 2012-08-15 AAK Patent B.V. Procédé de diagnostic du syndrome du côlon irritable
EP3144004A1 (fr) 2009-10-06 2017-03-22 Scott Dorfner Formulations antibiotiques présentant une réduction des effets secondaires gastro-intestinaux et des rechutes d'infections difficiles par clostridium et procédés associés
CN102946891B (zh) 2009-11-11 2017-09-01 营养健康有限公司 益生菌双歧杆菌菌株
MY162183A (en) 2009-12-01 2017-05-31 Univ Putra Malaysia Probiotic composition for nutraceutical product
US10212954B2 (en) 2009-12-18 2019-02-26 Colgate-Palmolive Company Pet food compositions including probiotics and methods of manufacture and use thereof
JP5557520B2 (ja) 2009-12-22 2014-07-23 京楽産業．株式会社 遊技機の演出用動力伝達機構及びこれを備える遊技機
US20150104418A1 (en) 2014-12-18 2015-04-16 Microbios, Inc. Bacterial composition
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
NL2004200C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
JP5737646B2 (ja) 2010-03-24 2015-06-17 森下仁丹株式会社 抗アレルギー剤
EP2552464B1 (fr) 2010-03-30 2018-02-28 Assistance Publique - Hôpitaux de Paris Utilisation de bifidobacteries destinee a la prevention d'allergies aux nourissons allaites.
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011149335A1 (fr) 2010-05-25 2011-12-01 N.V. Nutricia Composition nutritionnelle d'empreinte immunitaire
CA2836413A1 (fr) 2010-06-01 2011-12-08 Moore Research Enterprises Llc Constituants cellulaires issus de bacteries du genre bacteroides, compositions en contenant et methodes therapeutiques utilisant des bacteries du genre bacteroides ou des constituants cellulaires de celles-ci
WO2011151941A1 (fr) 2010-06-04 2011-12-08 国立大学法人東京大学 Composition présentant une activité d'induction de la prolifération ou de l'accumulation de cellule t régulatrice
TWI417054B (zh) 2010-06-15 2013-12-01 Jen Shine Biotechnology Co Ltd 新穎糞腸球菌ｌｊｓ－０１及其益生用途
EP2397145A1 (fr) 2010-06-18 2011-12-21 Nestec S.A. L. johnsonii La1, B. longum NCC2705 et troubles immunitaires
FR2962045B1 (fr) 2010-07-05 2012-08-17 Bifinove Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
CN101914452B (zh) * 2010-07-14 2011-12-07 洪亚辉 石杉碱甲高产菌株tcm-01
TWI401086B (zh) 2010-07-20 2013-07-11 Univ China Medical 胚芽乳酸桿菌及其用途
KR102157718B1 (ko) 2010-07-26 2020-09-18 큐 바이올로직스 인코포레이티드 면역원성 소염 조성물
CA2807242C (fr) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions pour une transplantation florale de matieres fecales et leurs procedes de fabrication et d'utilisation et dispositifs pour leur administration
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
KR101250463B1 (ko) 2010-10-12 2013-04-15 대한민국 신생아 분변에서 분리한 내산소성 비피도박테리움 롱검 비피더스 유산균 및 이를 이용한 프로바이오틱 조성물
WO2012055408A1 (fr) 2010-10-27 2012-05-03 Quantibact A/S Capture d'adn et d'arn cibles par des sondes comprenant des molécules intercalaires
CN102031235B (zh) 2010-11-09 2012-07-25 中国农业大学 一种粪肠球菌anse228及其应用
EP2455092A1 (fr) 2010-11-11 2012-05-23 Nestec S.A. Protection de micro-organismes probiotiques sans réplication contre les infections des voies respiratoires supérieures
US20120128644A1 (en) 2010-11-24 2012-05-24 Oragenics, Inc. Use of Bacteria to Treat and Prevent Respiratory Infections
CN102093967B (zh) 2010-12-02 2013-01-30 中国农业科学院特产研究所 一株水貂源屎肠球菌及其应用
ES2389547B1 (es) 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
MX361355B (es) 2011-01-10 2018-12-04 Cleveland Biolabs Inc Uso del agonista del receptor tipo toll para el tratamiento del cáncer.
EP2481299B1 (fr) 2011-01-31 2016-12-07 Dr. Fischer Gesundheitsprodukte GmbH Souches de bifidobacterium bifidum pour application dans les maladies gastro-intestinales
JP5840368B2 (ja) 2011-02-02 2016-01-06 カルピス株式会社 関節炎予防改善用物質
WO2012108830A1 (fr) 2011-02-09 2012-08-16 Lavivo Ab Compositions symbiotiques pour la restauration et la reconstitution du microbiote intestinal
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
WO2012140636A1 (fr) 2011-04-11 2012-10-18 Alimentary Health Limited Formulation probiotique
WO2012142605A1 (fr) 2011-04-15 2012-10-18 Samaritan Health Services Agent de déploiement de recolonisation rapide
SG194542A1 (en) 2011-04-20 2013-12-30 Mico Bio Inc Composition and method for enhancing an immune response
US9567361B2 (en) 2011-05-13 2017-02-14 Glycosyn LLC Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
KR20120133133A (ko) 2011-05-30 2012-12-10 한국 한의학 연구원 생약 추출물 또는 이의 유산균 발효물을 포함하는 호흡기 질환의 예방 또는 치료용 조성물
WO2012170478A2 (fr) 2011-06-06 2012-12-13 The University Of North Carolina At Chapel Hill Procédés et trousses pour la détection d'adénomes, d'un cancer colorectal, et leurs utilisations
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
GB201110095D0 (en) 2011-06-15 2011-07-27 Danisco Method of treatment
JP2013005759A (ja) 2011-06-24 2013-01-10 Kyodo Milk Industry Co Ltd マウス腸内菌叢の推測方法
CN102408998B (zh) * 2011-06-28 2013-06-05 深圳大学 一种具有神经退行性疾病防治活性的海洋红树耐盐性内生真菌
WO2013005836A1 (fr) 2011-07-07 2013-01-10 長岡香料株式会社 Inhibiteur d'absorption de fructose
WO2013008102A2 (fr) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Procédés et compositions pour évaluer et/ou traiter des maladies immunitaires chroniques
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
CN102304483A (zh) 2011-08-12 2012-01-04 北京金泰得生物科技股份有限公司 一株饲用屎肠球菌及其应用
KR101261872B1 (ko) 2011-08-23 2013-05-14 대한민국 (식품의약품안전처장) 장내 미생물 효소복합체 및 이의 제조방법
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013053836A1 (fr) 2011-10-11 2013-04-18 Quantum Pharmaceuticals Sa Composition comprenant un microbiote intestinal humain cultivé en conditions anaérobie
FI126711B (fi) 2011-10-12 2017-04-13 Gut Guide Oy Serotoniinivajeeseen liittyvän terveysriskin arvioiminen
CN103082292B (zh) 2011-11-02 2015-03-04 深圳华大基因研究院 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用
CN102373172B (zh) 2011-11-03 2013-03-20 北京龙科方舟生物工程技术有限公司 一株屎肠球菌及其应用
CN108676774B (zh) 2011-12-01 2023-05-09 国立大学法人东京大学 诱导调节性t细胞的增殖或积累的人源细菌
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido láctica probiótica
ITBG20120010A1 (it) 2012-02-24 2013-08-25 Milano Politecnico Dispositivo per l'addestramento chirurgico
ITMI20120471A1 (it) 2012-03-26 2013-09-27 Giovanni Mogna Composizione a base di ceppi di batteri bifidobacterium longum in grado di aiutare il prolungamento della vita
JP5792105B2 (ja) 2012-03-27 2015-10-07 森永乳業株式会社 ラクト−ｎ−ビオースｉの製造方法
JP6201982B2 (ja) 2012-03-30 2017-09-27 味の素株式会社 糖尿病誘起細菌
US20130280724A1 (en) 2012-04-11 2013-10-24 Nestec Sa Methods for diagnosing impending diarrhea
CN104507483A (zh) 2012-04-13 2015-04-08 波士顿学院理事会 益生元组合物及使用方法
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
ES2792106T3 (es) 2012-05-18 2020-11-10 Genome Res Ltd Métodos y grupos
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
WO2013181694A1 (fr) 2012-06-04 2013-12-12 Gaurav Agrawal Compositions et procédés de traitement de la maladie de crohn et des pathologies et infections associées
CN106620189B (zh) 2012-06-06 2021-11-19 上海交通大学 改善肠道菌群结构的方法及应用
US9676847B2 (en) 2012-06-25 2017-06-13 Orega Biotech IL-17 antagonist antibodies
BR112015001884B1 (pt) 2012-07-31 2020-12-01 Société des Produits Nestlé S.A. composição nutricional para promover a saúde musculoesquelética em pacientes com doença inflamatória intestinal (ibd), seu uso, e formulação farmacêutica, formulação nutricional, formulação de alimentação por tubo, suplemento alimentar, alimento funcional ou produto de bebida
US20150211053A1 (en) 2012-08-01 2015-07-30 Bgi-Shenzhen Biomarkers for diabetes and usages thereof
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
KR101426276B1 (ko) * 2012-08-16 2014-08-05 주식회사한국야쿠르트 심장질환 및 뇌졸중을 유발하는 거품세포 형성 억제 및 혈관 병변 형성을 억제하는 활성을 가지는 락토바실러스 플란타룸 ｈｙ７７１２를 유효성분으로 함유하는 제품
JP2015531770A (ja) 2012-08-29 2015-11-05 サリックス ファーマシューティカルズ，インコーポレイテッド 緩下剤組成物、ならびに便秘および関連胃腸疾患および症状を処置するための方法
WO2014036182A2 (fr) 2012-08-29 2014-03-06 California Institute Of Technology Diagnostic et traitement du trouble du spectre autistique
EP2894985A4 (fr) 2012-09-13 2016-09-28 Massachusetts Inst Technology Profils d'administration de médicaments programmables de bactéries ciblées par une tumeur
KR101473058B1 (ko) 2012-09-19 2014-12-16 주식회사 쎌바이오텍 과민성 대장 증후군 예방 또는 치료용 조성물
CN103652322B (zh) 2012-09-21 2016-02-10 临沂思科生物科技有限公司 一种含乳酸菌的复合益生菌饲料添加剂的制备方法
WO2014053608A1 (fr) 2012-10-03 2014-04-10 Metabogen Ab Identification d'une personne ayant un risque d'athérosclérose et de maladies associées par le microbiome intestinal de la personne et prévention de telles maladies
FR2997091B1 (fr) 2012-10-22 2016-05-06 Fond Mediterranee Infection Utilisation d'un compose antioxydant pour la culture de bacteries sensibles a la tension en oxygene
WO2014067976A1 (fr) 2012-10-30 2014-05-08 Nestec S.A. Compositions comprenant des microparticules et des probiotiques permettant d'apporter un effet immunitaire synergique
US9839657B2 (en) 2012-10-30 2017-12-12 Deerland Enzymes, Inc. Prebiotic compositions comprising one or more types of bacteriophage
JP2015535280A (ja) 2012-11-01 2015-12-10 レイクスユニフェルシテイト フローニンゲン 胃腸管において有益な細菌を刺激する方法及び組成物
WO2014075745A1 (fr) 2012-11-19 2014-05-22 Université Catholique de Louvain Utilisation d'akkermansia pour le traitement de troubles métaboliques
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102617655B1 (ko) 2012-11-23 2023-12-27 세레스 테라퓨틱스, 인코포레이티드 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
JP2016501852A (ja) 2012-11-26 2016-01-21 トーマス・ジュリアス・ボロディ 糞便微生物叢の回復のための組成物、ならびにそれらを作製および使用する方法
WO2014093655A2 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Fabrication et optimisation de systèmes, de procédés et de compositions pour la manipulation de séquence avec des domaines fonctionnels
DK3064585T3 (da) 2012-12-12 2020-04-27 Broad Inst Inc Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation
SG11201504523UA (en) 2012-12-12 2015-07-30 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US20140193464A1 (en) 2013-01-08 2014-07-10 Imagilin Technology, Llc Effects of probiotics on humans and animals under environmental or biological changes
KR20230110367A (ko) 2013-02-04 2023-07-21 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
EP2951283A4 (fr) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions et procédés
EP3536328B1 (fr) 2013-02-22 2021-10-27 The Regents of The University of California Produit alimentaire ou boisson, ou composition probiotique, comprenant lactobacillus johnsonii 456
CN105228635A (zh) 2013-03-05 2016-01-06 格罗宁根大学 Faecalibacterium prausnitzii HTF-F（DSM 26943）在抑制炎症中的应用
NZ711298A (en) 2013-03-14 2021-07-30 Therabiome Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
WO2014153194A2 (fr) 2013-03-14 2014-09-25 Seres Health, Inc. Procédés de détection de pathogènes et d'enrichissement à partir de matériaux et de compositions
EP2967077A4 (fr) 2013-03-15 2016-09-14 Seres Therapeutics Inc Compositions microbiennes et procédés associés basés sur un réseau
US9669059B2 (en) 2013-03-15 2017-06-06 University Of Florida Research Foundation, Incorporated Butyrogenic bacteria as probiotics to treat clostridium difficile
WO2014150139A1 (fr) 2013-03-15 2014-09-25 Microbiome Therapeutics, Llc. Fibre de cosse de soja activée
CN103156888A (zh) 2013-03-18 2013-06-19 广州知光生物科技有限公司 脆弱拟杆菌在制备治疗炎症性肠病组合物中的应用
CN103142656A (zh) 2013-03-18 2013-06-12 广州知光生物科技有限公司 脆弱拟杆菌在制备防治结肠癌组合物中的应用
CN103146620A (zh) 2013-03-25 2013-06-12 广州知光生物科技有限公司 具有益生菌特性的脆弱拟杆菌
JP2014196260A (ja) 2013-03-29 2014-10-16 公立大学法人奈良県立医科大学 慢性閉塞性肺疾患の予防又は治療用組成物
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
JP6079876B2 (ja) 2013-05-31 2017-02-15 日本電気株式会社 分散処理システム
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
JP6330032B2 (ja) 2013-06-05 2018-05-23 レビオティクス インコーポレイテッドＲｅｂｉｏｔｉｘ，Ｉｎｃ． 微生物叢回復療法組成物を製造、処理、および梱包するための方法
WO2014201037A2 (fr) 2013-06-10 2014-12-18 New York University Procédés permettant de manipuler des réponses immunitaires par altération du microbiote
WO2014200334A1 (fr) 2013-06-14 2014-12-18 N.V. Nutricia Composition synbiotique pour le traitement d'infections chez des patients allergiques
WO2015003001A1 (fr) 2013-07-01 2015-01-08 The Washington University Procédés pour identifier des compléments qui augmentent la colonisation intestinale par une espèce bactérienne isolée, et compositions dérivées
WO2015003305A1 (fr) 2013-07-08 2015-01-15 吉瑞高新科技股份有限公司 Étui de cigarette électronique
WO2015006355A2 (fr) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions contenant des combinaisons de molécules bioactives dérivées d'une microflore pour le traitement d'une maladie
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
WO2015017625A1 (fr) 2013-07-31 2015-02-05 Wikifoods, Inc. Compositions d'aliment fonctionnel enrobé
EP3033091B1 (fr) 2013-08-16 2022-09-07 Versitech Limited Composition probiotique et utilisation de celle-ci dans la prevention et le traitement du carcinome hepatocellulaire
CN103509741B (zh) 2013-08-22 2015-02-18 河北农业大学 布劳特菌auh-jld56及其在牛蒡苷元转化中的应用
CN104415060A (zh) 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
US10203329B2 (en) 2013-09-12 2019-02-12 The Johns Hopkins University Biofilm formation to define risk for colon cancer
US10058576B2 (en) 2013-10-03 2018-08-28 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
PL3071052T3 (pl) 2013-10-18 2020-07-27 Innovachildfood Ab Zbilansowany pod względem odżywczym złożony posiłek dla niemowląt i małych dzieci oraz sposób otrzymywania wspomnianego posiłku
PL229020B1 (pl) 2013-11-13 2018-05-30 Inst Biotechnologii Surowic I Szczepionek Biomed Spolka Akcyjna Nowy szczep Bifidobacterium breve
US10258655B2 (en) * 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2015095241A2 (fr) 2013-12-16 2015-06-25 Seres Health, Inc. Compositions bactériennes et leurs méthodes d'utilisation pour traiter des troubles du système immunitaire
CN103981115B (zh) 2013-12-24 2018-10-26 北京大伟嘉生物技术股份有限公司 一株高抗逆性屎肠球菌及其应用
CN103981117B (zh) 2013-12-24 2018-10-26 北京大伟嘉生物技术股份有限公司 一株高抗逆性屎肠球菌及其培养方法和应用
CN103820363B (zh) 2014-01-27 2016-02-24 福建省农业科学院生物技术研究所 一种屎肠球菌菌粉的制备与应用
CN103865846B (zh) 2014-02-27 2016-03-30 扬州绿保生物科技有限公司 一种屎肠球菌及其制备方法
CN103849590B (zh) 2014-03-25 2016-07-06 上海交通大学 一株耐酸短双歧杆菌BB8dpH及其应用
KR101683474B1 (ko) 2014-03-26 2016-12-08 주식회사 쎌바이오텍 과민성 대장 증후군 예방 또는 치료용 조성물
US9783858B2 (en) 2014-04-02 2017-10-10 Northwestern University Altered microbiome of chronic pelvic pain
KR101583546B1 (ko) 2014-04-09 2016-01-11 국립암센터 유전자 다형성을 이용한 소라페닙 치료에 대한 반응성 예측방법
CN106659746A (zh) 2014-04-10 2017-05-10 国立研究开发法人理化学研究所 用于诱导th17细胞的组合物及方法
CN104195075B (zh) 2014-08-14 2017-04-19 生合生物科技股份有限公司 一种屎肠球菌ef08及包含它的饲料添加物和饲料
WO2015168534A1 (fr) 2014-05-02 2015-11-05 Novogy, Inc. Traitement thérapeutique de déséquilibres microbiens gastro-intestinaux par déplacement de microbes compétitif
SG11201608835VA (en) 2014-05-08 2016-11-29 Panoptes Pharma Ges M B H Compounds for treating ophthalmic diseases and disorders
CN106687130B (zh) 2014-08-05 2020-01-21 深圳华大基因科技有限公司 真杆菌属在预防和治疗结直肠癌相关疾病中的用途
CN106573044B (zh) 2014-08-05 2020-01-21 深圳华大基因科技有限公司 真杆菌属在预防和治疗结直肠癌相关疾病中的用途
WO2016033439A2 (fr) 2014-08-28 2016-03-03 Yale University Compositions et méthodes pour le traitement d'une maladie ou d'un trouble inflammatoire
US20160058808A1 (en) 2014-09-03 2016-03-03 California Institute Of Technology Microbe-based modulation of serotonin biosynthesis
CN104546935A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546932A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546940A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 平常拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546933A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546942A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 多氏拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546934B (zh) 2014-09-30 2019-04-09 深圳华大基因科技有限公司 粪副拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
WO2016057671A1 (fr) 2014-10-07 2016-04-14 University Of Virginia Patent Foundation Compositions et procédés pour la prévention et le traitement d'infection
CA2965663C (fr) 2014-10-24 2023-04-04 Evolve Biosystems, Inc. Bifidobacteries activees et leurs methodes d'utilisation
JP6800846B2 (ja) 2014-10-30 2020-12-16 カリフォルニア インスティチュート オブ テクノロジー 神経発達症群における行動の改善のための細菌含有組成物、及び細菌を使用することを含む、神経発達症群における行動の改善のための方法
CN107106616A (zh) 2014-10-30 2017-08-29 加利福尼亚技术学院 包括改善神经发育障碍行为的细菌的组合物和方法
EP3881680A1 (fr) 2014-10-31 2021-09-22 Pendulum Therapeutics, Inc. Procédés et compositions se rapportant à un traitement microbien de troubles
CN104435000A (zh) 2014-11-12 2015-03-25 江南大学 乳酸菌对支气管哮喘治疗中的应用
CN107249609A (zh) 2014-11-25 2017-10-13 纪念斯隆-凯特琳癌症中心 肠道微生物群和gvhd
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2016102951A1 (fr) 2014-12-23 2016-06-30 4D Pharma Research Limited Polypeptide pirin et modulation immunitaire
ME02997B (fr) 2014-12-23 2018-10-20 4D Pharma Res Ltd Une lignée de bacteroides thetaiotaomicron et son utilisation pour la réduction des inflammations
CN104560820B (zh) 2014-12-30 2017-10-20 杭州师范大学 屎肠球菌kq2.6及应用
US20160199425A1 (en) * 2015-01-08 2016-07-14 Nubiome, Inc. Treatment and Prophylaxis for Parkinson's Disease
KR20170128247A (ko) 2015-01-23 2017-11-22 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암 예방에서 단쇄 지방산의 용도
CN105982919A (zh) 2015-02-26 2016-10-05 王汉成 生物减速剂抗癌技术
WO2016139217A1 (fr) 2015-03-04 2016-09-09 Ab-Biotics, S.A. Composition comprenant un microbiote intestinal humain cultivé en conditions anaérobies
EP3270938A4 (fr) 2015-03-18 2018-12-19 Whole Biome Inc. Méthodes et compositions se rapportant à un traitement microbien et au diagnostic de troubles cutanés
US20180078587A1 (en) 2015-03-18 2018-03-22 Trustees Of Tufts College Compositions and methods for preventing colorectal cancer
KR101745084B1 (ko) 2015-05-06 2017-06-09 한양대학교 산학협력단 메가스페라 헥사노이카 균주를 이용하여 헥사노익산을 생산하는 방법
KR20160131237A (ko) * 2015-05-06 2016-11-16 한양대학교 산학협력단 C5-c8 유기산을 생산하는 신규 균주 및 이를 이용하여 c5-c8 유기산을 생산하는 방법
JP2018521013A (ja) 2015-06-01 2018-08-02 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 共生微生物叢の操作による癌の処置
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PL3206700T3 (pl) 2015-06-15 2019-11-29 4D Pharma Res Ltd Kompozycje zawierające szczepy bakteryjne
MD3307288T2 (ro) 2015-06-15 2019-12-31 4D Pharma Res Ltd Compoziții care conțin tulpini bacteriene
MA41060B1 (fr) * 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN115364122A (zh) 2015-06-15 2022-11-22 4D制药研究有限公司 包含细菌菌株的组合物
WO2017031371A1 (fr) 2015-08-20 2017-02-23 Api Holdings, Llc Formulations et procédés pour favoriser la santé de l'abeille à miel
CN105112333A (zh) 2015-08-31 2015-12-02 江南大学 一种具有良好肠道定殖能力的长双歧杆菌及筛选方法和应用
EP3370748B1 (fr) 2015-11-03 2022-06-08 The Brigham and Women's Hospital, Inc. Microbiote thérapeutique pour le traitement et/ou la prévention de l'allergie alimentaire
EA034677B1 (ru) 2015-11-20 2020-03-05 4Д Фарма Рисёрч Лимитед Композиции для лечения или профилактики рака, содержащие штамм enterococcus gallinarum
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
KR20180083894A (ko) 2015-11-24 2018-07-23 세레스 테라퓨틱스, 인코포레이티드 설계된 박테리아 조성물
WO2017091753A1 (fr) 2015-11-25 2017-06-01 Memorial Sloan-Kettering Cancer Center Procédés et compositions pour réduire une infection ou colonisation d'enterococci résistant à la vancomycine
JP2019503688A (ja) 2016-01-11 2019-02-14 ３ピーエルダブリュー リミテッド 多糖分解酵素を分泌するように遺伝子改変された乳酸利用細菌
DK3313423T3 (da) 2016-03-04 2019-05-20 4D Pharma Plc Sammensætninger omfattende bakterielle blautia-stammer til behandling af visceral hypersensitivitet
AU2017234120B2 (en) 2016-03-14 2024-06-20 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
JP6898628B2 (ja) 2016-06-15 2021-07-07 国立大学法人広島大学 神経変性疾患治療剤
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
IT201600091033A1 (it) 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
WO2018094190A2 (fr) 2016-11-18 2018-05-24 Sanford Burnham Prebys Medical Discovery Institute Microbiote intestinal et traitement du cancer
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018112363A1 (fr) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Méthodes de traitement du cancer à l'aide de parabacteroides
WO2018112365A2 (fr) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Procédés de traitement du cancer colorectal et d'un mélanome en utilisant parabacteroides goldsteinii
CN106890196A (zh) 2017-04-07 2017-06-27 青岛东海药业有限公司 酪酸梭菌在制备预防或治疗帕金森病制剂中的应用
WO2018215782A1 (fr) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprenant des souches bactériennes
HUE052258T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Megasphaera nemzetségbe tartozó baktériumtörzset tartalmazó készítmény, és alkalmazása
IL283973B (en) 2017-06-14 2022-08-01 4D Pharma Res Ltd Preparations containing bacterial strains
AU2018298087A1 (en) 2017-07-05 2020-01-23 Evelo Biosciences, Inc. Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis
CN112601534A (zh) 2018-05-11 2021-04-02 4D制药研究有限公司 包含细菌菌株的组合物
EP3893905A1 (fr) 2018-12-12 2021-10-20 4D Pharma Research Limited Compositions comprenant des souches bactériennes

Also Published As

Publication number Publication date
EP3600364A1 (fr) 2020-02-05
JP2022088641A (ja) 2022-06-14
JP6837581B2 (ja) 2021-03-03
CA3066557A1 (fr) 2018-12-20
LT3804737T (lt) 2022-07-11
AU2018283994A1 (en) 2020-02-06
EP3804737A1 (fr) 2021-04-14
SI3600364T1 (sl) 2020-10-30
WO2018229236A2 (fr) 2018-12-20
US20210315943A1 (en) 2021-10-14
ES2823053T3 (es) 2021-05-07
PT3600364T (pt) 2020-10-19
US20200215126A1 (en) 2020-07-09
EP3804737B1 (fr) 2022-05-18
US11779613B2 (en) 2023-10-10
HUE059249T2 (hu) 2022-11-28
ES2917415T3 (es) 2022-07-08
CN110913876A (zh) 2020-03-24
PT3804737T (pt) 2022-08-29
KR20200018463A (ko) 2020-02-19
CY1123565T1 (el) 2022-03-24
US20200206280A1 (en) 2020-07-02
BR112019026677A2 (pt) 2020-06-30
MA49010B1 (fr) 2020-11-30
WO2018229236A3 (fr) 2019-03-07
IL271265B (en) 2022-06-01
NZ760654A (en) 2021-03-26
DK3600364T3 (da) 2020-08-31
MX2021006456A (es) 2021-07-02
RS60910B1 (sr) 2020-11-30
PL3804737T3 (pl) 2022-09-12
SG11201912156QA (en) 2020-01-30
IL271319A (en) 2020-01-30
BR112019026667A2 (pt) 2020-06-23
SG11201912153VA (en) 2020-01-30
CA3066561A1 (fr) 2018-12-20
US11007233B2 (en) 2021-05-18
JP2020523326A (ja) 2020-08-06
CA3066561C (fr) 2022-07-19
JP2020523313A (ja) 2020-08-06
AU2021203891A1 (en) 2021-07-08
DK3804737T3 (da) 2022-07-25
AU2020204099A1 (en) 2020-07-09
WO2018229216A1 (fr) 2018-12-20
EP3638273A2 (fr) 2020-04-22
EP4104843A1 (fr) 2022-12-21
IL271265A (en) 2020-01-30
MD3804737T2 (ro) 2022-10-31
CY1125659T1 (el) 2024-02-16
HRP20220747T1 (hr) 2022-10-14
NZ760605A (en) 2022-03-25
IL292373A (en) 2022-06-01
AU2018283994B2 (en) 2021-03-18
AU2018285453A1 (en) 2020-02-06
MD3600364T2 (ro) 2020-12-31
SI3804737T1 (sl) 2022-07-29
TWI812624B (zh) 2023-08-21
AU2018285453B2 (en) 2020-03-19
PL3600364T3 (pl) 2021-01-11
KR102519483B1 (ko) 2023-04-10
HUE052258T2 (hu) 2021-04-28
MA53937A (fr) 2021-04-14
TW201919668A (zh) 2019-06-01
MA49010A (fr) 2020-02-05
CN111032061A (zh) 2020-04-17
MA53937B1 (fr) 2022-05-31
RS63393B1 (sr) 2022-08-31
CA3160116A1 (en) 2018-12-20
HRP20201629T1 (hr) 2020-12-25
NZ773323A (en) 2022-03-25
LT3600364T (lt) 2020-10-26
EP3600364B1 (fr) 2020-08-05
JP2021075556A (ja) 2021-05-20
US11660319B2 (en) 2023-05-30
TW201919667A (zh) 2019-06-01
KR20200015575A (ko) 2020-02-12

Similar Documents

Publication Publication Date Title
MA49425A (fr) Compositions comprenant des souches bactériennes
MA42351A (fr) Compositions comprenant des souches bactériennes
MA41708A (fr) Compositions comprenant des souches bactériennes
MA45287A (fr) Compositions comprenant des souches bactériennes
MA52860A (fr) Compositions comprenant des souches bactériennes
MA47230A (fr) Compositions comprenant des souches bactériennes
MA51639A (fr) Compositions comprenant des souches bactériennes
MA51455A (fr) Compositions comprenant des souches bactériennes
MA52128A (fr) Compositions comprenant des souches bactériennes
DK3600363T3 (da) Sammensætninger omfattende bakteriestammer
MA48940A (fr) Compositions comprenant des souches bactériennes
DK3638271T3 (da) Sammensætninger omfattende bakteriestammer
MA49982A (fr) Compositions comprenant des souches bactériennes
GB201708182D0 (en) Compositions comprising bacterial strains
MA53860A (fr) Compositions comprenant des souches bactériennes
MA53155A (fr) Compositions comprenant des souches bactériennes
MA53228A (fr) Compositions comprenant des souches bactériennes
MA51709A (fr) Compositions comprenant des souches bactériennes
MA49322A (fr) Compositions comprenant des souches bactériennes
MA54074A (fr) Compositions comprenant des souches bactériennes
GB201718551D0 (en) Compositions comprising bacterial strains
GB201714309D0 (en) Compositions comprising bacterial strains
GB201714298D0 (en) Compositions comprising bacterial strains
GB201712857D0 (en) Compositions comprising bacterial strains
GB201712851D0 (en) Compositions comprising bacterial strains